One retrospective matched cohort study found no significant increase in risk of NAION or ION in patients taking semaglutide or any GLP-1 RA compared to matched controls with type 2 diabetes or high BMI [5]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.